Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors

Journal of Hepatology

Volumn 61, Issue 1, 2014, Pages S98-S107

  Welzel, Tania Mara ^a   Dultz, Georg ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

All oral; Direct acting antiviral agents (DAAs); Host targeting agents (HTAs).; Interferon free HCV treatment; Non nucleoside polymerase inhibitors (NNI); NS3 4A protease inhibitors (PI); NS5A inhibitors

Indexed keywords

ABT 072; ABT 450; ACH 3102; ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; DACLATASVIR; DASABUVIR; GRAZOPREVIR; GSK 2336805; MK 8742; OMBITASVIR; RIBAVIRIN; SAMATASVIR; SIMEPREVIR; SOVAPREVIR; TMC 647055; UNCLASSIFIED DRUG; INTERFERON; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; NUCLEIC ACID SYNTHESIS INHIBITOR; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; TELAPREVIR; VIRUS PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PILOT STUDY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; NUCLEIC ACID SYNTHESIS INHIBITORS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84913555486     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.08.014     Document Type: Review

References (67)

1. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and S.T. Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
2. B. Hajarizadeh, J. Grebely, and G.J. Dore Epidemiology and natural history of HCV infection Nat Rev Gastroenterol Hepatol 10 2013 553 562
3. V. Lohmann, F. Körner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113
4. V. Lohmann, and R. Bartenschlager On the history of hepatitis C virus cell culture systems J Med Chem 57 2014 1627 1642
5. R. Bartenschlager, V. Lohmann, and F. Penin The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection Nat Rev Microbiol 11 2013 482 496
6. J.M. Pawlotsky (Guest Editor) New hepatitis C therapies Semin Liver Dis 34 2014 7 8
7. J.M. Baugh, J.A. Garcia-Rivera, and P.A. Gallay Host-targeting agents in the treatment of hepatitis C: a beginning and an end? Antiviral Res 100 2013 555 561
8. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
9. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, Adrian M. Di Bisceglie, and K.R. Reddy Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
10. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
11. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
12. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
13. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
14. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, and R.H. Hyland Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
15. M. Sulkowski, I.M. Jacobson, R. Ghalib, M. Rodriguez-Torres, Z. Younossi, and A. Corregidor Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS Study subgroup analysis J Hepatol 60 2014 S4
16. E. Lawitz, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, and M.S. Sulkowski Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with Metavir F3-4 (Cohort 2) J Hepatol 60 2014 S524
17. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
18. N. Afdhal, S. Zeuzem, P. Kwo, M. Chojkier, N. Gitlin, and M. Puoti Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Engl J Med 370 2014 1889 1898
19. N. Afdhal, K.R. Reddy, D.R. Nelson, E. Lawitz, S.C. Gordon, and E. Schiff Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
20. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, and E. Lawitz Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
21. I. Gentile, A.R. Buonomo, F. Borgia, E. Zappulo, G. Castaldo, and G. Borgia MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection Expert Opin Investig Drugs 23 2014 719 728
22. T. Ng, T. Reisch, T. Middleton, K. McDaniel, D. Kempf, and L. Lu ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotype coverage Top Antivir Med 22 2014 314
23. C.A. Coburn, P.T. Meinke, W. Chang, C.M. Fandozzi, D.J. Graham, and B. Hu Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity ChemMedChem 8 2013 1930 1940
24. G. Cheng, M. Yu, B. Peng, Y. Lee, A. Trejo-Martin, and R. Gong 1191 GS-5816, a second generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage and a high resistance barrier J Hepatol 58 2013 S484
25. J. Walker, R. Crosby, A. Wang, E. Woldu, J. Vamathevan, and C. Voitenleitner Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A Antimicrob Agents Chemother 58 2014 38 47
26. T. Ng, P. Krishnan, W. Kati, T. Reisch, L. Lu, and T. Dekhtyar ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high barrier to resistance Top Antivir Med 22 2014 315
27. K.V. Kowdley, E. Lawitz, F. Poordad, D.E. Cohen, D.R. Nelson, and S. Zeuzem Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 N Engl J Med 370 2014 222 232
28. E. Lawitz, C. Hezode, P. Varunok, P.J. Thuluvath, T. Baykal, and M. Kapoor Interferon- and ribavirin-free regimen of ABT-450/r + ABT-267 in HCV genotype 1b-infected treatment-naïve patients and prior null responders Hepatology 58 2013 62A
29. C. Hezode, P. Marcellin, S. Pol, T. Hassanein, K. Fleischer-Stepniewska, and T. Baykal Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450/R + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection J Hepatol 60 2014 S24
30. < http://www.clinicaltrials.gov/ct2/show/NCT02068222 > [accessed on 30.08.14].
31. A. Muir, F. Poordad, A. Sheikh, M. Elkashab, and R. Brennan SVR4 results for the combination of ACH-3102 and sovaprevir, with ribavirin, in subjects with genotype 1 chronic hepatitis C infection Hepatol Int 8 2014 395
32. < http://ir.achillion.com/releasedetail.cfm?releaseid=853707 > [accessed on 03.08.14].
33. Y. Suzuki, K. Ikeda, F. Suzuki, J. Toyota, Y. Karino, and K. Chayama Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 58 2013 655 662
34. A.S. Lok, D.F. Gardiner, C. Hézode, E.J. Lawitz, M. Bourlière, and G.T. Everson Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders J Hepatol 60 2014 490 499
35. H. Kumada, Y. Suzuki, K. Ikeda, J. Toyota, Y. Karino, and K. Chayama Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 59 2014 2083 2091
36. M. Manns, S. Pol, I. Jacobson, P. Marcellin, S. Gordon, and C. Peng All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results J Hepatol 60 2014 S524
37. S. Zeuzem, C. Hezode, J.P. Bronowicki, V. Loustad-Ratti, F. Gea, and M. Buti Daclatasvir in combination with simeprevir ± ribavirin for hepatitis C virus genotype 1 infection (Abstract 28LB) Top Antivir Med 22 2014 15 16
38. A study of pharmacokinetics, efficacy, safety, tolerability, of the combination of simeprevir (TMC435), daclatasvir (BMS-790052), and ribavirin (RBV) in patients with recurrent chronic hepatitis C genotype 1b infection after orthotopic liver transplantation - Full text view - ClinicalTrials.gov: May 19, 2014; available from: http://www.clinicaltrials.gov/ct2/show/NCT01938625.
39. E. Lawitz, M. Rodriguez-Torres, T. Nguyen, A. Sheikh, H. Tobias, and J. Galati A phase II study of samatasvir (IDX719) in combination with simeprevir and ribavirin in treatment naïve HCV-infected subjects with genotypes 1b and 4 (HELIX-1 study) J Hepatol 60 2014 S495
40. E. Lawitz, J.M. Vierling, A. Murillo, M. Kugelmas, J. Gerstoft, and P. Winkle High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genotype 1 infected patients: the C- WORTHY Study Hepatology 58 2013 62A
41. C. Hezode, L. Serfaty, J.M. Vierling, M. Kugelmas, B. Pearlman, and W. Sievert Safety and efficacy of the all-oral regimen of MK-5172/MK-8742 ± ribavirin in treatment-naïve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: The C-WORTHY study J Hepatol 60 2014 S5
42. E. Lawitz, C. Hezode, E. Gane, E. Tam, M. Lagging, and L. Balart Efficacy and safety of MK-5172 AND MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: The C-WORTHY study J Hepatol 60 2014 S25
43. Search of: MK-5172 - List results - ClinicalTrials.gov: May 19, 2014; available from: http://www.clinicaltrials.gov/ct2/results?term=MK-5172&Search=Search.
44. Search of: MK-8742 - List results - ClinicalTrials.gov: May 19, 2014; available from: http://www.clinicaltrials.gov/ct2/results?term=MK-8742&Search=Search.
45. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, and S. Siggelkow Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
46. E. Lawitz, F. Poordad, K.V. Kowdley, D.E. Cohen, T. Podsadecki, and S. Siggelkow A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 J Hepatol 59 2013 18 23
47. P. Krishnan, R. Tripathi, M. Irvin, J. Beyer, T. Reisch, and G. Schnell Lack of impact of baseline resistance associated variants (RAVS) on treatment outcome in the aviator study with ABT-450/r, ABT-333, and ABT-267 +/- RBV J Hepatol 60 2014 S498
48. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, and D. Crawford Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
49. S. Zeuzem, I.M. Jacobson, T. Baykal, R.T. Marinho, F. Poordad, and M. Bourlière Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
50. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, and K. Agarwal ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
51. P. Ferenci, D. Bernstein, J. Lalezari, D. Cohen, Y. Luo, and C. Cooper ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
52. P. Andreone, M.G. Colombo, J.V. Enejosa, I. Koksal, P. Ferenci, and A. Maieron ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365
53. P. Kwo, P. Mantry, E. Coakley, H. Te, H. Vargas, and R. Brown Results of the phase 2 study M12-999: interferon-free regimen of ABT-450/r/ABT-267 + ABT-333 + ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection J Hepatol 60 2014 S47
54. G.T. Everson, K.D. Sims, M. Rodriguez-Torres, C. Hézode, E. Lawitz, and M. Bourlière Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection Gastroenterology 146 2014 420 429
55. G.T. Everson, K.D. Sims, P.J. Thuluvath, E. Lawitz, T. Hassanein, and M. Rodriguez-Torres LB-1: phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection Hepatology 58 2013 1377A
56. T. Hassanein, K. Sims, M. Bennett, N. Gitlin, E. Lawitz, and T. Nguyen All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naïve patients with chronic HCV genotype 4 infection J Hepatol 60 2014 S472
57. UNITY 1: a study of an investigational treatment regimen of daclatasvir (DCV) + asunaprevir (ASV) + BMS-791325 in a fixed dose combination (the DCV 3DAA (direct acting antiviral) regimen) for 12 weeks for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in non-cirrhotic subjects - Full text view - ClinicalTrials.gov: May 19, 2014; available from: < http://www.clinicaltrials.gov/ct2/show/NCT01979939 >.
58. UNITY 2: a study of an investigational treatment regimen of DCV+ASV+BMS-791325 in a fixed dose combination (the DCV 3DAA (direct acting antiviral) regimen) with or without RBV for 12 weeks for the treatment of chronic hepatitis C virus(HCV)genotype 1 infection in subjects with compensated cirrhosis - Full text view - ClinicalTrials.gov: May 19, 2014; available from: < http://www.clinicaltrials.gov/ct2/show/NCT01973049 >.
59. UNITY 3: a Japanese phase 3 study of a daclatasvir/asunaprevir/BMS-791325 in subjects with genotype 1 chronic hepatitis C - Full text view - ClinicalTrials.gov: May 19, 2014; available from: < http://www.clinicaltrials.gov/ct2/show/NCT02123654 >.
60. A study to evaluate the safety, tolerability, and effectiveness of a 12-week combination therapy of TMC647055 and TMC435 with and without gsk23336805 with a pharmacokinetic enhancer with and without ribavirin in patients infected with chronic genotype 1 hepatitis C virus - Full text view - ClinicalTrials.gov: May 19, 2014; available from: < http://www.clinicaltrials.gov/ct2/show/NCT01724086 >.
61. J. Paeshuyse, A. Kaul, E. de Clercq, B. Rosenwirth, J. Dumont, and P. Scalfaro The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
62. U. Chatterji, M. Bobardt, S. Selvarajah, F. Yang, H. Tang, and N. Sakamoto The isomerase active site of cyclophilin A is critical for hepatitis C virus replication J Biol Chem 284 2009 16998 17005
63. L. Coelmont, S. Kaptein, J. Paeshuyse, I. Vliegen, J. Dumont, and G. Vuagniaux Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrob Agents Chemother 53 2009 967 976
64. P.A. Thibault, and J.A. Wilson Targeting miRNAs to treat hepatitis C virus infections and liver pathology: inhibiting the virus and altering the host Pharmacol Res 75 2013 48 59
65. Harry L.A. Janssen, H.W. Reesink, E.J. Lawitz, S. Zeuzem, M. Rodriguez-Torres, and K. Patel Treatment of HCV infection by targeting microRNA N Engl J Med 368 2013 1685 1694
66. Miravirsen in combination with telaprevir and ribavirin in null responder to pegylated-interferon alpha plus ribavirin subjects with chronic hepatitis C virus infection - Full text view - ClinicalTrials.gov: April 27, 2014; available from: < http://clinicaltrials.gov/ct2/show/NCT01872936 >.
67. Efficacy and safety of MK-5172, MK-8742, and Sofosbuvir for chronic infection with hepatitis C virus genotypes 1 and 3 (MK-5172-074) - Full text view - ClinicalTrials.gov: May 21, 2014; available from: < http://www.clinicaltrials.gov/ct2/show/NCT02133131 >.